Table 1.
(A) rhAPC inhalation | (B) Increased rhAPC inhalation | |||
---|---|---|---|---|
Saline | 100 μg APC | Saline | 100 μg APC | |
TNFα (pg/ml) | 733.8±84.44 | 440.0±71.91* | 797.9±67.14 | 448.8±33.79*** |
IL-6 (pg/ml) | 954.2±92.31 | 604.1±125.0* | 1088±167.2 | 587.2±152.3* |
TATc (ng/ml) | 9.55±2.20 | 4.39±1.19* | 8.40±0.76 | 5.15±0.75* |
(A) 100 μg rhAPC administered 30 min before and 3 h after LPS exposure compared to saline treatment also represented in Figure 1. (B) 100 μg rhAPC administered 30 min before and 1, 3 and 5 h after LPS exposure compared to saline treatment. Data shown are mean±s.e.
P<0.05
P<0.0001 vs saline treatment.